FDA 483 - Rentschler Biopharma Inc.

Baxalta US Inc. in Milford, MA, a drug substance manufacturer, was cited for significant deficiencies during an FDA inspection. The observations primarily concern inadequate quality control procedures, incomplete investigations, poor record-keeping, and insufficient quality oversight. These issues indicate a systemic lack of control over critical manufacturing and testing processes.